Impact of facility volume on therapy and survival for locally advanced cervical cancer

Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base

“…Early data evaluating survival outcomes by radiation oncology facility volume have mostly involved head and neck and cervical cancers . Chen et al used the NCDB to evaluate survival outcomes by facility volume for patients with locally advanced laryngeal cancer and confirmed that high‐volume centers were associated with improved OS .…”

“…Early data evaluating survival outcomes by radiation oncology facility volume have mostly involved head and neck and cervical cancers. [19][20][21][22][23] Chen et al used the NCDB to evaluate survival outcomes by facility volume for patients with locally advanced laryngeal cancer and confirmed that high-volume centers were associated with improved OS. 20 A similar study using the Surveillance, Epidemiology, and End Results-Medicare database also indicated that patients with locally advanced head and neck SCC had improved outcomes at high-volume centers, suggesting that this may be caused by multiple factors, including an increased likelihood of multidisciplinary involvement.…”

Disparities in radiation therapy delivery: current evidence and future directions in head and neck cancer

“…An increasing amount of data supports the hypothesis that radiation therapy by high-volume providers is associated with improved outcomes in HNC [13,14] and multiple non-HNC malignancies like lung, cervical, and prostate cancers [15][16][17][18]. In HNC, two recent large national database analyses have noted disparities in access to high-volume providers, which may serve as another proxy for access to high-quality cancer care.…”

Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study

“…Ovarian cancer remains the deadliest gynecologic malignancy, with relative 5-year survival rates for patients diagnosed with epithelial ovarian cancer (EOC) ranging from 17% to 90% depending on stage at diagnosis. 1 Treatment of ovarian cancer has evolved over several decades; the standard treatment for advanced-stage disease is either debulking surgery followed by chemotherapy or neoadjuvant chemotherapy with (or without) surgery. [2][3][4] Multiple studies have defined the role and efficacy of chemotherapy in ovarian cancer, showing increased progressionfree survival (PFS) and overall survival (OS) in patients receiving the standard treatment of combination platinum-and taxane-based chemotherapy, as recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer.…”